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Abstract
Introduction: Lhermitte-Duclos disease or dysplastic gangliocytoma of the cerebellum is an extremely rare tumor.
It is a slowly enlarging mass within the cerebellar cortex. The majority of cases are diagnosed in the third or fourth
decade of life.
Case presentation: We report the case of a 37-year-old Caucasian woman who underwent positron emission
tomography-computed tomography with fluorine-18-fluorodeoxyglucose for evaluation of a solitary lung node. No
pathological uptake was detected in the solitary lung node but the positron emission tomography-computed
tomography of her brain showed intense tracer uptake, suggestive of a malignant neoplasm, in a mass in her left
cerebellar lobe. Our patient had experienced two years of occipital headache and movement disorder.
Subsequently, magnetic resonance imaging was performed with contrast agent administration, showing a large
subtentorial mass in her left cerebellar hemisphere, with compression and dislocation of the fourth ventricle.
Metabolic data provided by positron emission tomography and morphological magnetic resonance imaging views
were fused in post-processing, allowing a diagnosis of dysplastic gangliocytoma with increased glucose
metabolism. Total resection of the tumor was performed and histological examination confirmed the diagnosis of
Lhermitte-Duclos disease.
Conclusions: Our case indicates that increased uptake of fluorine-18-fluorodeoxyglucose may be misinterpreted as
a neoplastic process in the evaluation of patients with Lhermitte-Duclos disease, but supports the usefulness of
integrated positron emission tomography-magnetic resonance imaging in the exact pathophysiologic explanation
of this disease and in making the correct diagnosis. However, an accurate physical examination and exact
knowledge of clinical data is of the utmost importance.
Introduction
Lhermitte-Duclos disease (LDD), or dysplastic cerebellar
gangliocytoma, is a rare tumor arising from the cerebel-
lar cortex, first described clinically in 1920 by Lhermitte
and Duclos [1]. The majority of cases are diagnosed in
the third or fourth decade of life [1]. The common
symptoms of this disease are due to the mass effect in
the posterior cranial fossa, associated with cerebellar
dysfunction, hydrocephalus and signs of increased intra-
cranial pressure.
Till now, the exact origin of LDD, whether neoplastic,
dysplastic or hamartomatous, is not well known; more
than 200 cases have been reported in the literature [2]
a n dt h e s er e p o r t si n d i c a t et h a ti ti sab e n i g nn e u r o g l i a l
tumor with undefined prognosis. On histopathology,
LDD is characterized by regional enlargement of the
cerebellar stratum granulosum, an absence of the
Purkinje cell layer and progressive hypertrophy of the
granular cell neurons with increased myelination [3,4].
Magnetic resonance imaging (MRI) is considered to be
the best modality imaging option for characterization of
L D Db ys o m ea u t h o r s[ 1 , 3 , 5 ]b u tt h ei m p a c to ff u n c -
tional imaging provided by nuclear medicine is recom-
mended in other studies [2,5,6]. Various authors have
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vided by positron emission tomography (PET) and sin-
gle-photon emission computed tomography in the
metabolic evaluation of LDD, by using radiotracers such
as fluorine-18-fluorodeoxyglucose (F18-FDG) [2,5,6],
thallium-201 [5] and C11-methionine [7]. The potential
added value of metabolic imaging lies in the possibility
to calculate metabolic activity of a lesion by the mea-
surement of the maximum standardized uptake value
(SUVmax), the ratio between the average radioactivity
registered in a lesion and the administered amount of
the same tracer [8].
The best therapeutic modality approach for this dis-
ease is represented by surgical intervention [9].
Here we describe a case of incidental LDD in a 37-
year-old woman.
Case presentation
A 37-year-old Caucasian woman came to our depart-
ment to undergo a total-body PET-computed tomogra-
phy (PET/CT) with F18-FDG for evaluation of a solitary
lung node. Her family history was unremarkable. During
clinical evaluation, she said she had been experiencing
occipital headache and movement disorder for two
years; therefore, in agreement with our patient, PET/CT
of her brain, using three-dimensional acquisition, was
performed after the total-body scan. Both PET/CT scans
were performed after intravenous administration of 300
MBq of F18-FDG and fasting of six hours; image acqui-
sition was performed with a hybrid Discovery
16ST
PET-CT system (GE Medical System, Milwaukee, TN,
USA).
No pathological uptake was detected corresponding to
a solitary lung node with a 12 mm maximum transverse
diameter and regular margins in the superior lobe of her
right lung, in the CT images, nor in her other examined
anatomic districts.
A CT scan of her brain, performed before a cerebral
PET scan, showed a hypodense mass in her left cerebel-
lar hemisphere. Brain PET revealed intense and focal
uptake of the tracer in the left hemisphere of her cere-
bellum, corresponding to the lesion discovered by CT,
with an SUVmax of 14, while the SUVmax in the contral-
ateral cerebellar hemisphere was 6.5 (Figure 1a).
Metabolic data were suggestive of a malignant condi-
tion. Four days later, MRI of her brain was performed.
This revealed a slightly-enhancing, bulky mass in her
right cerebellar hemisphe r et h a tm e a s u r e d5×4×3
cm. On T1-weighted images, the lesion was hypointense
and slightly enhancing after the administration of gado-
linium. The T2-weighted fluid-attenuated inversion
recovery (FLAIR) images showed the characteristic fea-
tures of LDD: striations representing the folia of the cer-
ebellum in association with hydrocephalus and
dislocation of the fourth ventricle (Figure 1b,c). MRI
was performed using a 3-T permanent magnet (GE
Medical System).
We fused the PET images with MRI views of our
patient. The comparative analysis of the images was
achieved by using the software Advantage MRI-PET
Fusion (GE Medical Systems), which is available on the
system’s workstation (Advantage Windows 4.4, GE Med-
ical Systems) and allows simultaneous analysis of
images. In particular, CT (obtained by co-registration
with PET) and MR images were first aligned by identify-
ing three or more pairs of corresponding landmarks to
align the anatomical images. Subsequently, once the MR
examination was sampled and adequately aligned with
CT data, unnecessary CT data were discarded and,
using the fusion software, were replaced by PET images.
Post-processing thus yielded a single PET/MRI examina-
tion resulting from the fusion of the brain PET images
with the brain MRI scans.
Image analysis of PET/MRI-fused images was per-
formed by a nuclear medicine physician and a radiolo-
gist. The borders of the lesion were correctly fused and
integrated PET/MRI views confirmed our suspicion that
F18-FDG was taken up heterogeneously within the
tumor, similarly to isointense bands of tissue in corre-
sponding T2-weighted FLAIR images. Furthermore, by
analysis of the PET/MRI images, we had confirmation of
a lesion with similar metabolism and intensity signal to
normal grey matter; the PET-only brain images sug-
gested a hypothesis of a malignant neoplasm (Figure 1d).
Subsequently, total surgical resection of the lesion was
performed and a histological examination confirmed the
diagnosis of LDD. Histological examination of speci-
mens revealed abnormal cerebellar cortical construction,
showing a rather inversely arranged cell-layer construc-
tion. Large neurons with clear nuclear bodies and smal-
ler neurons were present at the lateral sides of the folia.
Discussion
On CT, the typical finding of LDD is a hypodense cere-
bellar mass, without contrast enhancement; on MRI,
there is commonly a striated pattern of hypointensity on
T1-weighted images and a hyperintensity on T2-
weighted images alternating with isointense bands of
tissue.
In the present case, the clinical presentation and MRI
findings were in agreement with previously reported
cases in the literature [3,5]; similarly to other previous
studies, high level uptake of F18-FDG was observed
[2,5,6]. The reasons for the high uptake of F18-FDG
may be due to the overall high concentration of cerebel-
lar cortical cells with high density, which can simulate a
neoplasm. Taking this into account, we must underline
that LDD metabolic features when using F18-FDG need
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Page 2 of 5Figure 1 Axial positron emission tomography view. (a) Intense glucose metabolism in the left hemisphere of the cerebellum, corresponding
to a hypointense and slightly enhancing area with (b) maximum diameter of 5 cm in axial T1-weighted post contrast view. (c) Axial T2-
weighted fluid-attenuated inversion recovery images show the characteristic features of Lhermitte-Duclos disease: striations representing the folia
of the cerebellum in association with hydrocephalus and dislocation of the fourth ventricle. (d) Axial fused positron emission tomography-
magnetic resonance imaging views show the lesion with increased metabolism and intensity signal similar to that of normal grey matter.
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presence of an abnormal area of uptake in a cerebellar
hemisphere, we cannot rule out the possibility of a non-
malignant lesion.
MRI offers the possibility of correct identification of
the disease, within a known pattern of typical findings.
This suggested diagnostic tool as used in our case is
linked to the feasibility of software that allows the fusion
of metabolic imaging of PET with morphologic features
of MRI, without any meaningful loss of diagnostic per-
formance of either imaging modality [10].
New studies have focused on the possibility of evaluat-
ing MRI and PET in a single session: a recent paper
examined the potential added value of fusion imaging
PET/MRI in the evaluation of patients with cerebral
tumors. In that study, patients were examined with 18F-
FDOPA PET and by MRI; the authors concluded that
fusion imaging may improve performance of both mod-
alities, with the combination of the high sensitivity of
PET with the high spatial resolution power and specifi-
city of MRI. Combined 18F-FDOPA PET/MRI fusion
provided precise anatomic localization of tracer uptake
and well-labeled enhancing and non-enhancing tumor
areas as well. It is important to underline that, in a
small minority of cases, 18F-FDOPA activity identified a
tumor not visible on MRI [11].
The possibility of integrated PET/MRI evaluation of
the brain has a bigger value if we consider that new
radiotracers have been developed in the last decade for
the metabolic study of the brain. Recently, the feasibility
of tracers such as F18-choline for characterization of
low grade brain tumors [12] has been described, while
another radiopharmaceutical, C11-methionine, has been
employed in the evaluation of young patients with LDD.
In this last study, the cerebellar lesions presented a high
C11-methionine uptake (related to amino-acid hyperme-
tabolism) in a slowly growing lesion while no uptake
was detected in the resected tumors [7]. This fact sug-
gests the feasibility of this examination in evaluating the
efficacy of surgical treatment.
Considering the rapid development of new radiophar-
maceuticals for molecular imaging of brain tumors
[7,13], we can support the usefulness of integrated PET/
MRI in diagnosis. Although MRI provides accurate mor-
phological examination, the more important features of
molecular imaging with PET could provide a better pri-
mary diagnosis of brain tumors, identify a molecular tar-
get for therapy [13] and finally assess the response to
therapy.
Conclusions
Although the exact pathophysiologic features of LDD
are not well known, our case report indicates that
morphofunctional imaging reflects an important aspect
of this controversial disease: caution is needed in inter-
preting F18-FDG PET because the tracer can intensely
accumulate in LDD, mimicking a malignant tumor.
We suggest that correlative imaging with MRI and
accurate knowledge of the clinical history of the
patient are of the utmost importance. Simultaneous
evaluation of both fused imaging modalities may pro-
vide new insight on the study of the brain and its
changes in disease.
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